Literature DB >> 25198784

Catching the therapeutic window of opportunity in early Crohn's disease.

Silvio Danese, Gionata Fiorino, Carlos Fernandes, Laureal Peyrin-Biroulet1.   

Abstract

Crohn's disease (CD) is a chronic, disabling, progressive and destructive disease. The general goal of conventional step-up strategy in CD treatment is to treat and control symptoms. This strategy did not change the disease course and is now being replaced with a treat-to-target approach. Achieving deep remission (clinical remission and absence of mucosal ulcerations) is the target in CD in 2014. Inducing and maintaining deep remission is needed to prevent long-term outcomes such as bowel damage and disability in CD. Diagnostic delay is a common issue in CD and is associated with an increased risk of bowel damage over time. Identification of poor prognostic factors, risk stratification together with the development of "red flags" may result in early intervention with disease-modifying agents such as anti-TNF agents with the final aim of preventing overtreatment and avoiding undertreatment. Similar to rheumatoid arthritis, by catching the therapeutic window of opportunity in early CD and achieving deep remission, this could be the best way to change disease course (hospitalizations, surgeries, bowel damage, and disability) and patients' life.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25198784     DOI: 10.2174/1389450115666140908125738

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  13 in total

1.  Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease.

Authors:  Christopher Ma; Carla Ascoytia; Kelly P McCarrier; Mona Martin; Brian G Feagan; Vipul Jairath
Journal:  Dig Dis Sci       Date:  2018-06-29       Impact factor: 3.199

2.  Aspecific ileitis: Crohn's disease or not Crohn's disease? A prospective study.

Authors:  Cristina Bezzio; Ilaria Arena; Massimo Devani; Barbara Omazzi; Gianpiero Manes; Simone Saibeni
Journal:  Int J Colorectal Dis       Date:  2017-02-04       Impact factor: 2.571

3.  Diagnostic Delay in Crohn's Disease: Time for Red Flags.

Authors:  Gionata Fiorino; Silvio Danese
Journal:  Dig Dis Sci       Date:  2016-09-16       Impact factor: 3.199

4.  Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.

Authors:  Siddharth Singh; M Hassan Murad; Mathurin Fumery; Rocio Sedano; Vipul Jairath; Remo Panaccione; William J Sandborn; Christopher Ma
Journal:  Lancet Gastroenterol Hepatol       Date:  2021-10-22

Review 5.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

Review 6.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

Review 7.  Preventing Collateral Damage in Crohn's Disease: The Lémann Index.

Authors:  Gionata Fiorino; Cristiana Bonifacio; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  J Crohns Colitis       Date:  2016-01-07       Impact factor: 9.071

8.  Diagnostic Delay Is Associated with a Greater Risk of Early Surgery in a French Cohort of Crohn's Disease Patients.

Authors:  Stéphane Nahon; Pierre Lahmek; Thierry Paupard; Bruno Lesgourgues; Stanislas Chaussade; Laurent Peyrin-Biroulet; Vered Abitbol
Journal:  Dig Dis Sci       Date:  2016-05-20       Impact factor: 3.199

9.  Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease.

Authors:  Ryan C Ungaro; Saurabh Aggarwal; Ozlem Topaloglu; Wan-Ju Lee; Ryan Clark; Jean-Frederic Colombel
Journal:  Aliment Pharmacol Ther       Date:  2020-03-23       Impact factor: 8.171

Review 10.  Surgery versus Medical Therapy in Luminal Ileocecal Crohn's Disease.

Authors:  Michele Carvello; Silvio Danese; Antonino Spinelli
Journal:  Clin Colon Rectal Surg       Date:  2022-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.